# US 2023/0272009 A1 · Peptide, Peptide Salt, Pharmaceutical Composition and Biological Tissue Calcification Inhibitor

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0272009 A1
- Document ID: US20230272009A1
- Status: Published application
- Kind: A1
- Application number: 18/016,660
- Filed: 2021-07-16
- Published: 2023-08-31
- Earliest claimed: 2020-07-17
- Assignees: Hiroshima University
- Applicants: Hiroshima University
- Inventors: Yuji YOSHIKO; Tomoko MINAMIZAKI; Masaaki TOSHISHIGE; Shohei KOHNO
- Web page: https://patentgrep.com/patent/US20230272009A1

## CPC

- C07K 7/50: Cyclic peptides containing at least one abnormal peptide link
- A61P 9/14: Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- A61P 19/00: Drugs for skeletal disorders
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- C07K 14/47: from mammals
- C07K 14/70546: {Integrin superfamily}
- C07K 14/78: Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

A peptide or salt thereof includes an amino acid sequence set forth in SEQ ID NO:1 containing an amino acid sequence in which at least one of (a) the first aspartate residue and the second aspartate residue from the N-terminus, or (b) the 17th glycine residue and the 18th aspartate residue from the N-terminus is deleted. A peptide or salt thereof includes an amino acid sequence set forth in SEQ ID NO:5 containing an amino acid sequence in which the sixth aspartate residue from the N-terminus is substituted with another amino acid residue. The peptides or salts thereof include three specific serine residues of which at least two serine residues are phosphorylated, and have an action of inhibiting biotissue calcification.

## Claims

### Claim 1

(canceled)

### Claim 2

A peptide or salt thereof, comprising:
an amino acid sequence set forth in SEQ ID NO:5 containing
an amino acid sequence in which a sixth aspartate residue from an N-terminus is substituted with a glutamate residue, wherein
at least two serine residues are phosphorylated among three serine residues corresponding to ninth, 11th, and 13th serine residues from the N-terminus, wherein
the peptide or salt thereof has an action of inhibiting biotissue calcification.

### Claim 3

A peptide or salt thereof, comprising:
an amino acid sequence set forth in SEQ ID NO:9.

### Claim 4 (depends on 1)

The peptide or salt thereof according to claim 1, wherein the peptide or salt thereof is cyclic.

### Claim 5 (depends on 4)

The peptide or salt thereof according to claim 4, wherein the N-terminus and a C-terminus are linked to each other through a thioether bond between an acetylated amino group of the N-terminus and a thiol group of a cysteine residue added to the C-terminus.

### Claim 6 (depends on 2)

A pharmaceutical composition, comprising:
the peptide or salt thereof according to claim 2.

### Claim 7 (depends on 2)

A biotissue calcification inhibitor, comprising:
the peptide or salt thereof according to claim 2.

### Claim 8

A peptide or salt thereof, comprising:
an amino acid sequence set forth in SEQ ID NO:9, wherein
an N-terminus and a C-terminus are linked to each other through a thioether bond between an acetylated amino group of the N-terminus and a thiol group of a cysteine residue added to the C-terminus.

### Claim 9

A peptide or salt thereof, comprising:
an amino acid sequence set forth in SEQ ID NO:14, wherein
an amino group of a serine residue of an N-terminus is acetylated, and
the peptide or salt thereof becomes cyclic by a thioether bond between the acetyl group of the N-terminus and a thiol group of a cysteine residue of a C-terminus.
